Optimising Treatment As Prevention Strategies For Hepatitis C And HIV
Funder
National Health and Medical Research Council
Funding Amount
$471,809.00
Summary
New evidence shows how hepatitis C (HCV) and HIV transmission can be reduced dramatically through timely treatment initiation - treatment as prevention (TasP). TasP has re-focused attention on early HCV and HIV detection and treatment. Through observational studies, randomised control trials and the development of innovative surveillance systems, this fellowship will inform ways to maximise the potential of HCV and HIV prevention responses in Australia and internationally in this new TasP era.
Research Fellowship In Preventing HIV And HIV-related Cancer
Funder
National Health and Medical Research Council
Funding Amount
$772,490.00
Summary
This fellowship concerns HIV prevention and HIV-related cancer. In HIV prevention, Grulich will evaluate the success of elements of the new biomedical prevention approach to HIV, and highlight areas in which policy action can be taken to substantially reduce HIV transmission. In HIV related cancer, Grulich will determine whether HIV-associated cancers continue to occur at increased rates in the new era of prolonged survival of people with HIV, and investigate preventive approaches.
Anal Cancer Examination (ACE) Study - Annual Anal Examinations To Detect Early Anal Cancer In HIV Positive Men Who Have Sex With Men
Funder
National Health and Medical Research Council
Funding Amount
$60,926.00
Summary
Anal cancer is the most frequently occurring (non-AIDS defining) cancer in HIV positive men who have sex with men. There are still no guidelines for how to screen for this cancer. This research aims to determine the feasibility of implementing an annual anal examination to detect early anal cancer in HIV positive men who have sex with men.
The HIV Prevention Revolution: Measuring Outcomes And Maximising Effectiveness
Funder
National Health and Medical Research Council
Funding Amount
$1,081,723.00
Summary
There have been extra-ordinary recent biomedical advances in HIV prevention. These present an opportunity to turn the HIV epidemic around. We will undertake implementation research to optimise the impact of the new tools at the population level. NSW has a detailed HIV strategy with explicit targets for reduction of HIV transmission over the period 2012 to 2020. Our research will guide optimum program delivery to drive new HIV infections down in Australia and other high income settings.
A Pragmatic Randomised Clinical Trial Of Nicotine Vaporisers Added To Smoking Cessation Treatment For Priority Populations Living With Comorbidities
Funder
National Health and Medical Research Council
Funding Amount
$1,499,145.00
Summary
Smoking is a leading cause of early death for people with certain health conditions because they are more likely to smoke and are also at greater risk of tobacco-related disease. This clinical trial will test whether encouraging people living with Hepatitis C Virus, people on opiate substitution therapy and people living with HIV who smoke to use nicotine vaporisers long-term, in addition to current smoking cessation treatments, will help them to stay abstinent from smoking.